Literature DB >> 16415463

Do sulfonylurea drugs increase the risk of cardiac events?

David S H Bell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16415463      PMCID： PMC1329456          DOI： 10.1503/cmaj.051237

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

1.  Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.

Authors:  Scot H Simpson; Sumit R Majumdar; Ross T Tsuyuki; Dean T Eurich; Jeffrey A Johnson
Journal:  CMAJ       Date:  2006-01-17       Impact factor: 8.262

2.  Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans.

Authors:  P J Bijlstra; J A Lutterman; F G Russel; T Thien; P Smits
Journal:  Diabetologia       Date:  1996-09       Impact factor: 10.122

3.  Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris.

Authors:  K Ovünç
Journal:  Clin Cardiol       Date:  2000-07       Impact factor: 2.882

4.  Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes.

Authors:  Roldano Scognamiglio; Angelo Avogaro; Saula Vigili de Kreutzenberg; Christian Negut; Monica Palisi; Eros Bagolin; Antonio Tiengo
Journal:  Diabetes       Date:  2002-03       Impact factor: 9.461

5.  Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.

Authors:  C E Murry; R B Jennings; K A Reimer
Journal:  Circulation       Date:  1986-11       Impact factor: 29.690

6.  Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk.

Authors:  Kay-Tee Khaw; Nicholas Wareham; Sheila Bingham; Robert Luben; Ailsa Welch; Nicholas Day
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

7.  Impairment of myocardial protection in type 2 diabetic patients.

Authors:  Tsung-Ming Lee; Tsai-Fwu Chou
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

8.  Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics.

Authors:  Jose F Huizar; Luis A Gonzalez; James Alderman; Harton S Smith
Journal:  J Am Coll Cardiol       Date:  2003-09-17       Impact factor: 24.094

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction.

Authors:  F Andreotti; V Pasceri; D R Hackett; G J Davies; A W Haider; A Maseri
Journal:  N Engl J Med       Date:  1996-01-04       Impact factor: 91.245
View more
  14 in total

1.  Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930-936.

Authors:  J A Johnson; S H Simpson; D T Eurich; S R Majumdar
Journal:  Diabetologia       Date:  2006-06-21       Impact factor: 10.122

Review 2.  Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.

Authors:  James H O'Keefe; Mohammad Abuannadi; Carl J Lavie; David S H Bell
Journal:  Mayo Clin Proc       Date:  2011-01-26       Impact factor: 7.616

Review 3.  Effect of glucose-lowering therapies on heart failure.

Authors:  Michael Nassif; Mikhail Kosiborod
Journal:  Nat Rev Cardiol       Date:  2018-01-25       Impact factor: 32.419

Review 4.  [Pharmaceutical and insulin therapy of diabetes mellitus type 2. Update].

Authors:  E Siegel
Journal:  Internist (Berl)       Date:  2015-05       Impact factor: 0.743

Review 5.  Glycemic control and cardiovascular disease: what's a doctor to do?

Authors:  Preeti Kishore; Sharon H Kim; Jill P Crandall
Journal:  Curr Diab Rep       Date:  2012-06       Impact factor: 4.810

Review 6.  Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.

Authors:  Charles E Leonard; Sean Hennessy; Xu Han; David S Siscovick; James H Flory; Rajat Deo
Journal:  Trends Endocrinol Metab       Date:  2017-05-22       Impact factor: 12.015

Review 7.  Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.

Authors:  Linda A Gallo; Ernest M Wright; Volker Vallon
Journal:  Diab Vasc Dis Res       Date:  2015-01-23       Impact factor: 3.291

Review 8.  Inpatient treatment of type 2 diabetes.

Authors:  Thomas G K Breuer; Juris J Meier
Journal:  Dtsch Arztebl Int       Date:  2012-06-29       Impact factor: 5.594

9.  Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.

Authors:  M C T Fyfe; J R White; A Taylor; R Chatfield; E Wargent; R L Printz; T Sulpice; J G McCormack; M J Procter; C Reynet; P S Widdowson; P Wong-Kai-In
Journal:  Diabetologia       Date:  2007-04-06       Impact factor: 10.122

10.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Authors:  Ioanna Tzoulaki; Mariam Molokhia; Vasa Curcin; Mark P Little; Christopher J Millett; Anthea Ng; Robert I Hughes; Kamlesh Khunti; Martin R Wilkins; Azeem Majeed; Paul Elliott
Journal:  BMJ       Date:  2009-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.